AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Want to cut your energy bills? Here’s how five experts are doing it 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
ATLANTA, Feb. 23, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on March 1, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 10:00 AM ET, on Thursday, March 2, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, March 2, 2017, 10:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' Fourth Quarter 2016 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 [email protected]
